Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Citation

  • Authors: Scott, B., Shen, J., Nizzero, S., Boom, K., Persano, S., Mi, Y., Liu, X., Zhao, Y., Blanco, E., Shen, H., Ferrari, M., Wolfram, J.
  • Year: 2016
  • Journal: Pharmacol Res 111 413-421
  • Applications: in vitro / Protein/Peptide/Antibody / PULSin
  • Cell types:
    1. Name: MDA-MB-231
      Description: Human breast adenocarcinoma cells
      Known as: MDAMB231
    2. Name: MDA-MB-468

Method

PULSin was used in combination with a multistage vector system to facilitate cellular internalization of pyruvate decarboxylase. The cells were exposed to PULSin (1.2 l/well), pyruvate decarboxylase (0.3 g/well), or PULSin/pyruvate decarboxylase (0.3 g protein/1.2 l PULSin/well) in serum-free media for 4 h, after which the media was replaced with media containing 1% FBS.

Abstract

Cancer cells have high rates of glycolysis and lactic acid fermentation in order to fuel accelerated rates of cell division (Warburg effect). Here, we present a strategy for merging cancer and yeast metabolism to remove pyruvate, a key intermediate of cancer cell metabolism, and produce the toxic compound acetaldehyde. This approach was achieved by administering the yeast enzyme pyruvate decarboxylase to triple negative breast cancer cells. To overcome the challenges of protein delivery, a nanoparticle-based system consisting of cationic lipids and porous silicon were employed to obtain efficient intracellular uptake. The results demonstrate that the enzyme therapy decreases cancer cell viability through production of acetaldehyde and reduction of lactic acid fermentation.

Go to